Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Phenylpropanolamine→

Phenylpropanolamine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
14838-15-4
Molecular formula
C9H13NO
Molecular weight
151.21 g/mol
Drug class
Sympathomimetic aminepredominantly indirect adrenergic agonist and nasal decongestant
Mechanism of action
Primarily promotes norepinephrine release from sympathetic nerve terminals and also has direct agonist activity at adrenergic receptors. Alpha-adrenergic activity causes vasoconstriction of nasal mucosal vessels; beta-adrenergic effects may also occur.
Indications / reported uses
  • Historically used as an oral or topical nasal decongestant in some jurisdictions; current availability and permitted indications vary because of safety-related regulatory restrictions.
  • It has also been used as an appetite suppressant historically; this is not presented as a current routine therapeutic indication.

Sources: https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Term=%22Phenylpropanolamine%22%5BMeSH+Terms%5D · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D010665 · https://pubchem.ncbi.nlm.nih.gov/compound/10297

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Sympathomimetic amine; predominantly indirect adrenergic agonist and nasal decongestant

Mechanism of action

Primarily promotes norepinephrine release from sympathetic nerve terminals and also has direct agonist activity at adrenergic receptors. Alpha-adrenergic activity causes vasoconstriction of nasal mucosal vessels; beta-adrenergic effects may also occur.

General use cases

  • Historically used as an oral or topical nasal decongestant in some jurisdictions; current availability and permitted indications vary because of safety-related regulatory restrictions.
  • It has also been used as an appetite suppressant historically; this is not presented as a current routine therapeutic indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Phenylpropanolamine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phenylpropanolamine Permitted Daily Exposure (PDE) report (the Phenylpropanolamine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phenylpropanolamine Occupational Exposure Limit (OEL) report (the Phenylpropanolamine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.